Background Image
Previous Page  159 / 182 Next Page
Information
Show Menu
Previous Page 159 / 182 Next Page
Page Background

158

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

71

de Wit R, van Dam F, Abu-Saad HH, Loonstra S, Zandbelt L, van Buuren A, van der

Heijden K, Leenhouts G. Empirical comparison of commonly used measures to evaluate

pain treatment in cancer patients with chronic pain. Journal of Clinical Oncology 1999;

17: 1280-1287.

72

del Rosario MA, Martin AS, Ortega JJ, Feria M. Temporal sedation with midazolam for

control of severe incident pain. Journal of Pain and Symptom Management 2001; 21:

439-442.

73

Deutsche Gesellschaft für Schmerztherapie. Der Deutsche Schmerzfragebogen und das

Deutsche Schmerztagebuch DGS. 2005.

74

Deutsche Gesellschaft für Schmerztherapie. Der DGS PraxisFragebogen für tumorbe-

dingte Durchbruchschmerzen. 2012.

75

Dickman A. Integrated strategies for the successful management of breakthrough

cancer pain. Curr Opin Support Palliat Care 2011; 5(1): 8-14.

76

Doyle D, Hanks G, Cherny N, Calman K. Oxford Textbook of Palliative Medicine 2004:

298-316. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant

and non-malignant diseases: A review of prevalence, characteristics and mechanisms.

Eur J Pain. 2005; 9: 195-206.

77

Du Pen SL, Kharasch ED, Williams A, Peterson DG, Sloan DC, Hasche-Klunder H, Krembs

AW. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain 1992;

49: 293-300.

78

Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets. Am J Drug Deliv

2006; 4(1): 1-5.

79

Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD,

Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S,

Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath

P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L,

Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT. Core outcome domains

for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 9-19.

80

Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. epidural clonidine analgesia for

intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995; 61: 391-399.

81

Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of can-

cer pain: a meta-analysis. Anesthesia and Analgesia 1995; 80: 290-295.

82

Elsner F, Zeppetella G, Porta-Sales J, Tagarro I. Newer generation fentanyl transmucosal

products for breakthrough pain in opioid-tolerant cancer patients. Clin Drug Investig

2011; 31(9): 605-618.

83

Enting RH, Oldenmenger WH, van der Rijt CC, Koper P, Lieverse J, Sillevis SP. Nitrous

oxide is not beneficial for breakthrough cancer pain. Palliative Medicine 2002; 16(3):

257-259.

84

Enting RH, Oldenmenger WH, van der Rijt CC, Wilms EB, Elfrink EJ, Elswijk I, Sillevis

Smitt PA. A prospective study evaluating the response of patients with unrelieved can-

cer pain to parenteral opioids. Cancer 2002; 94: 3049-3056.

Literaturverzeichnis